PATENT CLAIM ANALYSIS

Application Number: 16027967
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "179100"]

Abstract:
Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

Claim (Index 2):
The immunoconjugate of  claim 1 , wherein the cytotoxic drug moiety is selected from the group consisting of an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, and an RNA polymerase II inhibitor.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 95.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11978122', '14517682', '12939533', '13796768', '15130667']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8192063120153875
- 35 USC 102 Novelty (BERT): 0.5456261460969206
- Combined Prediction Score: 0.7918482954235408
- Mean Citation Score: 384.160708
- Max Citation Score: 410.674
- Similarity Product: 322.53967696130275

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test